✦ LIBER ✦

Open controlled therapeutic trial of intravenous immunoglobulins in relapsing-remitting multiple sclerosis

✍ Scribed by A. Achiron; E. Pras; R. Gilad; C.R. Gordon; I. Ziv; I. Sarova-Pinhas; E. Melamed

Book ID: 119107963
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 68 KB
Volume: 35
Category: Article
ISSN: 0165-5728
DOI: 10.1016/0165-5728(91)90994-i

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL

✍ Khan, O. A.; Tselis, A.; Boster, A.; Fazekas, F.; Lublin, F.D.; Li, D.; Freedman 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 149 KB

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL

✍ Engel, W. K.; Fazekas, F.; Lublin, F.D.; Li, D.; Freedman, M.S.; Hartung, H.P.; 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 128 KB

Randomised placebo-controlled trial of m

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis

✍ Franz Fazekas; Florian Deisenhammer; Siegrid Strasser-Fuchs; Gerhard Nahler; Bru 📂 Article 📅 1997 🏛 The Lancet 🌐 English ⚖ 46 KB

Intravenous immunoglobulin treatment in

Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A randomized, double-blind multicenter, placebo-controlled trial

✍ A. Achiron; R. Gilad; S. Hassin; Y. Barak; U. Gabbay; I. Ziv; Y. Goldhamer; E. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Rituximab in relapsing-remitting multipl

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

✍ Amit Bar-Or; Peter A. J. Calabresi; Douglas Arnold; Clyde Markowitz; Stuart Shaf 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

## Abstract We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB